Name: Kairos Pharma, Ltd. (KAPA) Financial Statements
Creator: FinSpry

Kairos Pharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Kairos Pharma, Ltd. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.16	0.00	0.00	0.00	0.00
Gross Profit	-0.16	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	0.41	0.08	0.09	0.18	0.02
Selling, General & Administrative	1.77	1.47	0.48	1.66	1.03
Operating Expenses	2.18	1.71	0.57	1.94	1.05
Operating Income	-2.34	-1.71	-0.57	-1.94	-1.05
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.86	0.10	-0.46	0.16	-0.01
Other Income/Expense	-0.26	0.00	-0.02	-0.04	0.00
Income
Income Before Tax	-2.60	-1.81	-1.05	-2.15	-1.05
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-2.60	-1.81	-1.05	-2.15	-1.05
Net Income - Continuous Operations	-2.60	-1.81	-1.05	-2.15	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-1.58	-1.55	-0.41	-1.88	0.00
EBIT	-2.41	-1.71	-0.57	-1.98	-1.05
Depreciation & Amortization	0.16	0.16	0.16	0.10	0.00
Earnings Per Share
Basic EPS	-	-	-	-	-
Diluted EPS	-	-	-	-	-
Basic Shares Outstanding	11.36	11.22	10.24	10.85	9.45
Diluted Shares Outstanding	11.36	11.22	10.24	10.85	9.45